Quantcast

Latest Venlafaxine Stories

2008-06-03 09:01:36

WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, despite physicians' desire to prescribe more serotonin/norepinephrine reuptake inhibitors (SNRIs), Forest Laboratories' Lexapro retains leadership among first-line therapies in the treatment of major depression. According to the new report entitled Treatment Algorithms in Major Depression, selective serotonin reuptake...

231fafd94407f45101c223c00650b0771
2008-02-26 00:50:00

A new study by scientists in the U.S., Canada and Britain has called into question the effectiveness of anti-depressant medications, including the popular Prozac and Paxil.According to the study, which included a comprehensive review of data from trials conducted before the drugs were approved in the U.S., the antidepressants work no better than placebos in many patients, and appear to help only those who are severely depressed.The researchers obtained the data from all the clinical trials,...

2007-08-10 06:04:23

The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential. The development of Pristiq (desvenlafaxine succinate) for fibromyalgia was terminated during the...

3471cecb79734a5f5ae940ca31dde76c1
2007-04-17 17:20:00

CHICAGO -- Authors of a new comprehensive analysis of antidepressants for children and teenagers say the benefits of treatment trump the small risk of increasing some patients' chances of having suicidal thoughts and behaviors. The risk they found is lower than the one the Food and Drug Administration identified in 2004, the year the agency warned the public about the drugs' risks in children. After the warning, U.S. youth suicides increased and some mental health experts said reluctance to...

2006-07-19 14:50:00

WASHINGTON (Reuters) - Information about risks to newborns and migraine sufferers linked to some of the world's most widely used antidepressants should be added to the drug labels, the U.S. Food and Drug Administration said on Wednesday. The FDA warned that taking antidepressants known as SSRIs -- including Prozac and Zoloft -- or certain SNRIs in combination with migraine drugs known as triptans could result in a life-threatening condition called serotonin syndrome. It also warned consumers...

2006-07-19 13:24:11

WASHINGTON (Reuters) - The use of some migraine drugs with certain antidepressants can cause a fatal condition in which patients experience hallucinations, overactive reflexes and rapid heart beat, the U.S. Food and Drug Administration warned on Wednesday. The antidepressants of concern include selective serotonin reuptake inhibitors and selective serotonin/norepinephrine reuptake inhibitors, the FDA said. Patients should talk to their doctors before discontinuing antidepressant or...

2006-05-23 13:37:53

By Ransdell Pierson NEW YORK (Reuters) - Shares of Wyeth fell on Tuesday following the disclosure that an experimental anti-depressant, which was designed to be improvement over its top-selling Effexor XR drug, caused nausea in many patients in a clinical trial. Wyeth shares were down $1.25, or 2.6 percent, to $47.58 in afternoon trading on the New York Stock Exchange. Data from a late-stage trial of the anti-depressant, called DVS-233, were presented on Monday at a scientific...

2006-05-23 13:35:00

By Ransdell Pierson NEW YORK (Reuters) - Shares of Wyeth fell on Tuesday following the disclosure that an experimental anti-depressant, which was designed to be improvement over its top-selling Effexor XR drug, caused nausea in many patients in a clinical trial. Wyeth shares were down $1.25, or 2.6 percent, to $47.58 in afternoon trading on the New York Stock Exchange. Data from a late-stage trial of the anti-depressant, called DVS-233, were presented on Monday at a scientific meeting of the...

2006-03-23 00:35:00

By Karla Gale NEW YORK -- A new study shows that when patients with major depression fail to respond to a course of Celexa (citalopram) or cannot tolerate its side effects, approximately one third of those whose treatment is augmented with either bupropion (Wellbutrin) or Buspar (buspirone) will experience a remission of their depression. If they are instead switched to Wellbutrin, Zoloft (sertraline), or Effexor (venlafaxine), about one out of four will remit. These findings, based on two...

2006-03-07 18:10:00

By Clementine Wallace NEW YORK (Reuters Health) - A single injection of the hormone medroxyprogesterone acetate (MPA) is more effective in reducing menopausal hot flashes than is treatment with the antidepressant pill venlafaxine (Effexor), researchers report. Hormones like MPA and recently marketed antidepressants have been shown to reduce hot flashes, but until now, no comparisons between the two treatments had been made. In a new report in the Journal of Clinical Oncology, a team led by...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.